AR056013A1 - Hemifumarato de derivado de piperidina - Google Patents

Hemifumarato de derivado de piperidina

Info

Publication number
AR056013A1
AR056013A1 ARP060103359A ARP060103359A AR056013A1 AR 056013 A1 AR056013 A1 AR 056013A1 AR P060103359 A ARP060103359 A AR P060103359A AR P060103359 A ARP060103359 A AR P060103359A AR 056013 A1 AR056013 A1 AR 056013A1
Authority
AR
Argentina
Prior art keywords
hemifumarate
solvate
piperidine derivative
salt
chlorobenzyl
Prior art date
Application number
ARP060103359A
Other languages
English (en)
Inventor
Bo-Goeran Josefsson
Julien Giovannini
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056013(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR056013A1 publication Critical patent/AR056013A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Hemifumarato de N-{2-[((2S)-3-{[1-(4-clorobencil)piperidin-4-il]amino}-2-hidroxi-2-metilpropil)oxi]-4-hidroxifenil}acetamida, o un solvato del mismo, composiciones farmacéuticas que contienen la sal o el solvato y uso de la sal o el solvato en terapias. Reivindicacion 3: El compuesto de acuerdo con la cláusula 2, caracterizado porque exhibe al menos los siguientes picos característicos de difraccion por rayos X de polvo (expresados en grados 2(Theta): a) 6,2, 10,7 y 12,5; o 6,2, 10,7 y 18,8; o c) 6,2, 10,7 y 18,0; o d) 6,2, 10,7, 12,5, 18,0 y 18,8; o e) 6,2, 10,7, 12,5, 18,0, 18,8, 19,7 y 19,8.
ARP060103359A 2005-08-02 2006-08-02 Hemifumarato de derivado de piperidina AR056013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0501769 2005-08-02

Publications (1)

Publication Number Publication Date
AR056013A1 true AR056013A1 (es) 2007-09-12

Family

ID=37708913

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103359A AR056013A1 (es) 2005-08-02 2006-08-02 Hemifumarato de derivado de piperidina

Country Status (16)

Country Link
US (1) US20080176902A1 (es)
EP (1) EP1912944A1 (es)
JP (1) JP2009503066A (es)
KR (1) KR20080031370A (es)
CN (1) CN101238104A (es)
AR (1) AR056013A1 (es)
AU (1) AU2006276346A1 (es)
BR (1) BRPI0614535A2 (es)
CA (1) CA2617406A1 (es)
IL (1) IL188484A0 (es)
MX (1) MX2008001114A (es)
NO (1) NO20081079L (es)
TW (1) TW200734305A (es)
UY (1) UY29713A1 (es)
WO (1) WO2007015668A1 (es)
ZA (1) ZA200800488B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69938193D1 (de) * 1998-11-20 2008-04-03 Hoffmann La Roche Piperidin ccr-3 rezeptor-hemmer
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
GB0021670D0 (en) * 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
SE0104251D0 (sv) * 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
TW200734305A (en) 2007-09-16
AU2006276346A1 (en) 2007-02-08
US20080176902A1 (en) 2008-07-24
NO20081079L (no) 2008-02-29
JP2009503066A (ja) 2009-01-29
ZA200800488B (en) 2008-12-31
IL188484A0 (en) 2008-04-13
CA2617406A1 (en) 2007-02-08
KR20080031370A (ko) 2008-04-08
MX2008001114A (es) 2008-03-11
BRPI0614535A2 (pt) 2011-04-05
EP1912944A1 (en) 2008-04-23
CN101238104A (zh) 2008-08-06
UY29713A1 (es) 2007-02-28
WO2007015668A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
BRPI0510500A (pt) composições farmacêuticas
AR057713A1 (es) Forma cristalina iii de la agomelatina, un procedimiento para su preparacion, y las composiciones farmaceuticas que la contienen
UY30440A1 (es) Nuevos compuestos
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
SV2009003281A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.0
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
IL188207A0 (en) Pyrrolidine derivatives and pharmaceutical compositions containing the same
AR029570A1 (es) Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
CY1112721T1 (el) Νεοι συνδετες που διαμορφωνουν τους υποδοχεις rαr, και χρηση αυτων στην ιατρικη για τον ανθρωπο και στα καλλυντικα
CY1108445T1 (el) Νεα μεθοδος συνθεσης και νεα κρυσταλλικη μορφη της αγομελατινης καθως και φαρμακευτικες συνθεσεις που την περιεχουν
MY138941A (en) Aryl-pyridine derivatives
UY30736A1 (es) Compuestos quimicos 537
AR054833A1 (es) Formas de dosificacion de liberacion retardada oral altamemte biodisponibles de succinato de o-desmetilvenlafaxina
PA8638201A1 (es) Forma cristalina alfa del ranelato de estroncio procedimiento para su preparacion y composiciones farmaceuticas que la contienen
MX2008001560A (es) Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
PA8669801A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
BRPI0603197A (pt) composição de toner
AR056013A1 (es) Hemifumarato de derivado de piperidina
CL2007003841A1 (es) Compuestos derivados de 4(5h-1 lambda-tiazol-2-il)piperidina; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar diabetes.
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
UY29712A1 (es) Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones
TR200504890T1 (tr) Benipidin hidroklorür içeren farmasötik bileşim
BR0312996A (pt) Sal de (s)-pantoprazol e seus hidratos
AR046254A1 (es) Productos farmaceuticos estables

Legal Events

Date Code Title Description
FA Abandonment or withdrawal